Alvotech (ALVO) vs Beam Therapeutics (BEAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Beam Therapeutics (BEAM) has outperformed Alvotech (ALVO) over the past year, losing 1.4% versus a loss of 32.3%. Beam Therapeutics is the larger company by market cap ($2.50 billion vs $2.01 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | BEAM |
|---|---|---|
| Share price | $5.64 | $24.23 |
| Market cap | $2.01B | $2.50B |
| 1-day change | -3.68% | -2.19% |
| YTD return | +14.04% | -10.64% |
| 1-year return | -32.29% | -1.43% |
| 5-year return | — | -73.41% |
| Forward P/E | 24.68 | — |
| EPS (TTM) | $-0.62 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $139.74M |
| Revenue growth (YoY) | — | +120.01% |
| Net income (latest FY) | — | $-79.99M |
| Operating margin | — | -274.57% |
| Net margin | — | -57.24% |
| 52-week high | $9.05 | $38.26 |
| 52-week low | $2.94 | $20.23 |
| Distance from 52-week high | -37.70% | -36.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +20.67% | +115.26% |
| Average volume | 1.05M | 1.92M |
| Shares outstanding | 356.82M | 103.29M |
| Employees | 1,279 | 540 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BEAM has outperformed ALVO by 30.9 percentage points over the past year.
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
ALVO vs BEAM FAQ
Which is bigger, Alvotech or Beam Therapeutics?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.50B compared with $2.01B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or BEAM?
BEAM returned -1.43% over the past 12 months, compared with -32.29% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Beam Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.